AQR CAPITAL MANAGEMENT LLC
Position in SLS — SELLAS Life Sciences Group, Inc.
CIK 1167557
Greenwich, CT
Position in SLS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$857,850
+$629,474 QoQ
Shares Held
58,120
+7.6% QoQ
Ownership
0.029%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#67
of 192 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026AQR CAPITAL MANAGEMENT LLC holds $5,658,888,286 across 216 Biotechnology names. SLS ranks #163 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,126,080 | $702,155,918 | |
| 2 | INCY |
Incyte Corp
|
5,320,901 | $603,177,333 | |
| 3 | EXEL |
Exelixis, Inc.
|
11,023,943 | $599,812,735 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
1,522,568 | $366,893,205 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
5,699,541 | $326,127,732 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
616,170 | $306,070,117 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
1,295,450 | $242,611,869 | |
| 8 | RPRX |
Royalty Pharma plc
|
4,305,412 | $241,404,446 |
All Filings in SLS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $857,850 | 58,120 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $228,376 | 53,990 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||